Amy Brenner hopes that a favorable FDA ruling will allow for more peptide products, noting her offices are in Kenwood and Mason.
1 report, 1 independent
Updated Sep 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Amy Brenner hopes that a favorable FDA ruling will allow for more peptide products, noting her offices are in Kenwood and Mason.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Amy Brenner
researcher
Nothing else this week.
Related events
- HHS policy changes regarding peptide access are affecting Olympia's facility.
- Allarity Therapeutics has established a facility in Horsholm, Northern Europe, and the FDA requires CLIA certification for biomarker testing.
- FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.
- HHS policy allows peptides in compounding pharmacies despite FDA lack of approval, with RFK Jr. arguing for safer compounds.